Lane R - Search Results

1

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.

Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R. Bullock R, et al. Among authors: lane r. Curr Med Res Opin. 2006 Mar;22(3):483-94. doi: 10.1185/030079906X89685. Curr Med Res Opin. 2006. PMID: 16574032 Clinical Trial.

2

Cholinesterase inhibition: is there evidence for disease-modifying effects?

Shanks M, Kivipelto M, Bullock R, Lane R. Shanks M, et al. Among authors: lane r. Curr Med Res Opin. 2009 Oct;25(10):2439-46. doi: 10.1185/03007990903209332. Curr Med Res Opin. 2009. PMID: 19678754 Review.

3

Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Bullock R, et al. Among authors: lane r. Curr Med Res Opin. 2005 Aug;21(8):1317-27. doi: 10.1185/030079905X56565. Curr Med Res Opin. 2005. PMID: 16083542 Clinical Trial.

4

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R. Touchon J, et al. Among authors: lane r. Curr Med Res Opin. 2006 Jan;22(1):49-59. doi: 10.1185/030079906x80279. Curr Med Res Opin. 2006. PMID: 16393430

5

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.

Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R. Blesa R, et al. Among authors: lane r. Pharmacogenet Genomics. 2006 Nov;16(11):771-4. doi: 10.1097/01.fpc.0000220573.05714.ac. Pharmacogenet Genomics. 2006. PMID: 17047484 Clinical Trial.

6

Butyrylcholinesterase genotype and gender influence Alzheimer's disease phenotype.

Lane RM, He Y. Lane RM, et al. Alzheimers Dement. 2013 Mar;9(2):e1-73. doi: 10.1016/j.jalz.2010.12.005. Epub 2012 Mar 7. Alzheimers Dement. 2013. PMID: 22402324 Review.

7

Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.

Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R. Hatoum HT, et al. Among authors: lane r. J Med Econ. 2009 Jun;12(2):98-103. doi: 10.3111/13696990903004039. J Med Econ. 2009. PMID: 19492974 Free article.

8

Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase.

Bullock R, Lane R. Bullock R, et al. Among authors: lane r. Curr Alzheimer Res. 2007 Jul;4(3):277-93. doi: 10.2174/156720507781077313. Curr Alzheimer Res. 2007. PMID: 17627485 Review.

9

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.

Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R. Ballard C, et al. Among authors: lane r. Curr Med Res Opin. 2008 Sep;24(9):2561-74. doi: 10.1185/03007990802328142. Epub 2008 Jul 31. Curr Med Res Opin. 2008. PMID: 18674411 Clinical Trial.

10

Emerging hypotheses regarding the influences of butyrylcholinesterase-K variant, APOE epsilon 4, and hyperhomocysteinemia in neurodegenerative dementias.

Lane RM, He Y. Lane RM, et al. Med Hypotheses. 2009 Aug;73(2):230-50. doi: 10.1016/j.mehy.2009.01.050. Epub 2009 Apr 8. Med Hypotheses. 2009. PMID: 19359103

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,064 results

Search Page

Filters